© 2000 American Heart Association, Inc.
Thrombosis |
Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors
From the Laboratory of Hematology (I.J.-V., P.E.M., M.C.A.), Centre de Détection et de Prévention de l’Athérosclerose (I.J.-V., J.F.R.), Statistics Department (J.G.), CHU Timone, Marseille, and Serbio Genevilliers (M.G.) and Stago Asnières (Y.G.), Asnières, France.
Correspondence to Prof I. Juhan-Vague, Laboratory of Hematology, CHU Timone, 13385 Marseille cedex 5, France. E-mail ijuhan{at}ap-hm.fr
Abstract—Thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently described fibrinolysis inhibitor that circulates in plasma as a procarboxypeptidase and is converted into an active form during coagulation. The physiological relevance of TAFI is not known, but it might be involved in pathways regulating fibrin deposition. Our aim was to determine the interindividual variability of plasma TAFI antigen values and their associations with conventional cardiovascular risk factors. Six hundred twenty-six consecutive patients (277 men) attending a metabolic ward for primary prevention were studied. TAFI antigen presented a large range of values, with a 2- to 3-fold increase between the 10th and 90th percentiles. No difference was observed between the 2 sexes. A significant correlation was observed between age and TAFI levels in women only. After adjustment for age, TAFI antigen was positively correlated in men for the waist-to-hip circumference ratio and blood pressure, whereas no significant correlation was observed in women. Stepwise multiple linear regression analysis indicated a low contribution of the parameters studied to the variability of TAFI antigen levels; the waist-to-hip circumference ratio accounted for only 2% in men, and age accounted for only 3% in women. Results were compared with those of fibrinogen and plasminogen activator inhibitor-1; cardiovascular risk factors in men and women accounted for 16% and 9.5%, respectively, of the fibrinogen variance and 36% and 32%, respectively, of the plasminogen activator inhibitor-1 variance. These observations did not attribute an important role to lifestyle characteristics in the control of TAFI antigen concentration in plasma. Because of the large interindividual variability of TAFI levels in plasma, genetic control may be involved.
Key Words: thrombin-activatable fibrinolysis inhibitor • cardiovascular risk • fibrinogen • plasminogen activator inhibitor-1
This article has been cited by other articles:
 |
|
 |
|
  M. B. Boffa, D. Maret, J. D. Hamill, N. Bastajian, P. Crainich, N. S. Jenny, Z. Tang, E. M. Macy, R. P. Tracy, R. F. Franco, et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis Blood, January 1, 2008; 111(1): 183 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Buffat, F. Boubred, F. Mondon, S. T. Chelbi, J.-M. Feuerstein, M. Lelievre-Pegorier, D. Vaiman, and U. Simeoni Kidney Gene Expression Analysis in a Rat Model of Intrauterine Growth Restriction Reveals Massive Alterations of Coagulation Genes Endocrinology, November 1, 2007; 148(11): 5549 - 5557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamamoto, K. Takeshita, T. Kojima, J. Takamatsu, and H. Saito Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly Cardiovasc Res, May 1, 2005; 66(2): 276 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Voetsch and J. Loscalzo Genetic Determinants of Arterial Thrombosis Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 216 - 229. [Abstract] [Full Text]
|
|
|
|
|
|
A. Gils, M.-C. Alessi, E. Brouwers, M. Peeters, P. Marx, J. Leurs, B. Bouma, D. Hendriks, I. Juhan-Vague, and P. J. Declerck Development of a Genotype 325-Specific proCPU/TAFI ELISA Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1122 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Montaner, M. Ribo, J. Monasterio, C. A. Molina, and J. Alvarez-Sabin Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke Stroke, April 1, 2003; 34(4): 1038 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Boffa, J. D. Hamill, D. Maret, D. Brown, M. L. Scott, M. E. Nesheim, and M. L. Koschinsky Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells J. Biol. Chem., March 7, 2003; 278(11): 9250 - 9257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Boffa, J. D. Hamill, N. Bastajian, R. Dillon, M. E. Nesheim, and M. L. Koschinsky A Role for CCAAT/Enhancer-binding Protein in Hepatic Expression of Thrombin-activable Fibrinolysis Inhibitor J. Biol. Chem., July 5, 2002; 277(28): 25329 - 25336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zitzmann, R. Junker, A. Kamischke, and E. Nieschlag Contraceptive Steroids Influence the Hemostatic Activation State in Healthy Men J Androl, July 1, 2002; 23(4): 503 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Juhan-Vague, P.E. Morange, H. Aubert, M. Henry, M.F. Aillaud, M.C. Alessi, A. Samnegard, E. Hawe, J. Yudkin, M. Margaglione, et al. Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Henry, H. Aubert, P. E. Morange, I. Nanni, M.-C. Alessi, L. Tiret, and I. Juhan-Vague Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled Blood, April 1, 2001; 97(7): 2053 - 2058. [Abstract] [Full Text] [PDF]
|
|